Physician profile
Win Toe
NPI 1144480682
$13,004.63
in general payments reported to CMS, 2019-2025
41 companies · $3,786 in 2025
The $3,786 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,313 · 2020: $567 · 2021: $1,590 · 2022: $1,402 · 2023: $1,769 · 2024: $579 · 2025: $3,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,133.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,638.22 | 2019-2023 | Tysabri, Vumerity |
| Alexion Pharmaceuticals, INC. | $1,178.67 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $860.61 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $835.43 | 2019-2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $684.35 | 2019-2021 | |
| Ucb, INC. | $568.04 | 2019-2025 | Nayzilam, Briviact, Neupro |
| Eisai INC. | $540.25 | 2023-2025 | |
| Pfizer INC. | $477.03 | 2025 | |
| Horizon Therapeutics Plc | $470.05 | 2022-2023 | Uplizna |
| Neurocrine Biosciences, INC. | $468.85 | 2022-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $458.15 | 2019-2025 | Ocrevus Zunovo |
| Genzyme Corporation | $382.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $380.16 | 2021-2022 | |
| Argenx US, INC. | $376.87 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $338.65 | 2019-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Win Toe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.